Adrenomedullin 2 attenuates LPS-induced inflammation in microglia cells by receptor-mediated cAMP-PKA pathway.
Animals
Cells, Cultured
Cyclic AMP
/ metabolism
Cyclic AMP-Dependent Protein Kinases
/ metabolism
Inflammation
/ metabolism
Inflammation Mediators
/ metabolism
Lipopolysaccharides
/ administration & dosage
Microglia
/ metabolism
Rats, Sprague-Dawley
Receptors, Cyclic AMP
/ metabolism
Signal Transduction
Adrenomedullin 2
Adrenomedullin receptor
Inflammation
Microglia
Protein kinase A
Receptor activity-modifying proteins
Journal
Neuropeptides
ISSN: 1532-2785
Titre abrégé: Neuropeptides
Pays: Netherlands
ID NLM: 8103156
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
30
03
2020
revised:
15
11
2020
accepted:
15
11
2020
pubmed:
1
12
2020
medline:
9
11
2021
entrez:
30
11
2020
Statut:
ppublish
Résumé
Inflammation plays a critical role in the development of neurodegenerative diseases. Adrenomedullin 2 (AM2), a member of the calcitonin gene-related peptide family, has been known to have anti-inflammatory effects. Here, we evaluated the anti-inflammatory effects of AM2 in LPS-activated microglia and BV2 cells. The endogenous mRNA and protein expressions of AM2, calcitonin receptor-like receptor (CLR), receptor activity-modifying proteins (RAMPs) including RAMP1, RAMP2 and RAMP3 and the production of inflammatory mediators including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) were detected by RT-PCR and Western blot. Our results revealed that LPS (1 μg/mL) significantly stimulated CLR, RAMP1, RAMP2 and RAMP3 protein expressions in BV2 microglia cells, but AM2 had a significant decrease. However, the mRNA levels of AM2, CLR, and RAMP1/2/3 were all markedly increased. LPS also induced obvious increases in mRNA and protein levels of the inflammatory mediators (TNF-α, IL-1β, COX2 and iNOS). More importantly, AM2 (10 nM) administration effectively inhibited the mRNA and protein expressions of these mediators induced by LPS and increased the cAMP content in LPS-stimulated BV2 cells. Furthermore, the antagonism with AM2 receptor antagonist IMD17-47, adrenomedullin (AM) receptor antagonist by AM22-52 or the inhibition of protein kinase A (PKA) activation by P1195 effectively prevented the inhibitory role of AM2 in LPS-induced production of the above inflammatory mediators. In conclusion, AM2 inhibits LPS-induced inflammation in BV2 microglia cells that may be mainly through AM receptor-mediated cAMP-PKA pathway. Our results indicate AM2 plays an important protective role in microglia inflammation, suggesting therapeutic potential for AM2 in neuroinflammation diseases caused by activated microglia.
Identifiants
pubmed: 33253929
pii: S0143-4179(20)30127-X
doi: 10.1016/j.npep.2020.102109
pii:
doi:
Substances chimiques
Inflammation Mediators
0
Lipopolysaccharides
0
Receptors, Cyclic AMP
0
Cyclic AMP
E0399OZS9N
Cyclic AMP-Dependent Protein Kinases
EC 2.7.11.11
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102109Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.